Ejemplos de código: curl


SELECT ?virus ?virusLabel ?work ?workLabel WITH {
  SELECT ?virus ?work WHERE {
    VALUES ?virus {
      wd:Q82069695 # SARS-CoV-2
      wd:Q16983360 # HKU1
      wd:Q16991954 # OC43
      wd:Q8351095  # NL63 
      wd:Q16983356 # 229E 
      wd:Q4902157  # MERS-CoV
      wd:Q278567   # SARS-CoV
    ?work wdt:P921 ?virus ;
          wdt:P921 wd:Q79460 .
  SERVICE wikibase:label { bd:serviceParam wikibase:language "es,en". }
ORDER BY ?virusLabel ?virus ?workLabel ?work

ejecutar o editar


virus work
Human coronavirus 229E (edit) Antibody to virus components in volunteers experimentally infected with human coronavirus 229E group viruses. (edit)
Human coronavirus 229E (edit) Detection of human coronavirus 229E-specific antibodies using recombinant fusion proteins. (edit)
Human coronavirus OC43 (edit) Development of a recombinant truncated nucleocapsid protein based immunoassay for detection of antibodies against human coronavirus OC43 (edit)
MERS-CoV (edit) A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. (edit)
MERS-CoV (edit) A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. (edit)
MERS-CoV (edit) A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV (edit)
MERS-CoV (edit) A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines (edit)
MERS-CoV (edit) Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. (edit)
MERS-CoV (edit) Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. (edit)
MERS-CoV (edit) Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. (edit)
MERS-CoV (edit) Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. (edit)
MERS-CoV (edit) Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. (edit)
MERS-CoV (edit) Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. (edit)
MERS-CoV (edit) Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. (edit)
MERS-CoV (edit) Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. (edit)
MERS-CoV (edit) Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection (edit)
MERS-CoV (edit) Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. (edit)
MERS-CoV (edit) Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. (edit)
MERS-CoV (edit) The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. (edit)
SARS coronavirus (edit) A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. (edit)
SARS coronavirus (edit) A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. (edit)
SARS coronavirus (edit) A human SARS-CoV neutralizing antibody against epitope on S2 protein. (edit)
SARS coronavirus (edit) A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies (edit)
SARS coronavirus (edit) Amino acids 15-28 in the ectodomain of SARS coronavirus 3a protein induces neutralizing antibodies. (edit)
SARS coronavirus (edit) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. (edit)
SARS coronavirus (edit) Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. (edit)
SARS coronavirus (edit) Antibodies to SARS coronavirus in civets. (edit)
SARS coronavirus (edit) Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. (edit)
SARS coronavirus (edit) Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. (edit)
SARS coronavirus (edit) Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. (edit)
SARS coronavirus (edit) Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. (edit)
SARS coronavirus (edit) Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. (edit)
SARS coronavirus (edit) Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein. (edit)
SARS coronavirus (edit) Characterization of monoclonal antibody against SARS coronavirus nucleocapsid antigen and development of an antigen capture ELISA. (edit)
SARS coronavirus (edit) Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). (edit)
SARS coronavirus (edit) Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. (edit)
SARS coronavirus (edit) Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. (edit)
SARS coronavirus (edit) DNA vaccine of SARS-Cov S gene induces antibody response in mice. (edit)
SARS coronavirus (edit) Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. (edit)
SARS coronavirus (edit) Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. (edit)
SARS coronavirus (edit) Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay (edit)
SARS coronavirus (edit) Disease-specific B Cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens. (edit)
SARS coronavirus (edit) Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. (edit)
SARS coronavirus (edit) Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing (edit)
SARS coronavirus (edit) Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. (edit)
SARS coronavirus (edit) Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants (edit)
SARS coronavirus (edit) Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library. (edit)
SARS coronavirus (edit) Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. (edit)
SARS coronavirus (edit) Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. (edit)
SARS coronavirus (edit) Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. (edit)
SARS coronavirus (edit) Label-free, electrical detection of the SARS virus N-protein with nanowire biosensors utilizing antibody mimics as capture probes (edit)
SARS coronavirus (edit) Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. (edit)
SARS coronavirus (edit) Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. (edit)
SARS coronavirus (edit) Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. (edit)
SARS coronavirus (edit) Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. (edit)
SARS coronavirus (edit) Neutralizing antibody response and SARS severity (edit)
SARS coronavirus (edit) Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. (edit)
SARS coronavirus (edit) Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. (edit)
SARS coronavirus (edit) Prevalence of IgG antibody to SARS-associated coronavirus in animal traders--Guangdong Province, China, 2003. (edit)
SARS coronavirus (edit) Profile of specific antibodies to the SARS-associated coronavirus. (edit)
SARS coronavirus (edit) Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. (edit)
SARS coronavirus (edit) Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. (edit)
SARS coronavirus (edit) SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. (edit)
SARS coronavirus (edit) SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. (edit)
SARS coronavirus (edit) SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus. (edit)
SARS coronavirus (edit) Sequential affinity purification of peroxidase tagged bispecific anti-SARS-CoV antibodies on phenylboronic acid agarose (edit)
SARS coronavirus (edit) Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus. (edit)
SARS-CoV-2 (edit) A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies (edit)
SARS-CoV-2 (edit) Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA and IgM antibodies (edit)
SARS-CoV-2 (edit) Antibody responses to SARS-CoV-2 short-lived (edit)
SARS-CoV-2 (edit) Characteristics and roles of SARS-CoV-2 specific antibodies in patients with different severities of COVID-19 (edit)
SARS-CoV-2 (edit) Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies (edit)
SARS-CoV-2 (edit) CoroNAT: Coronavirus neuraliserende antistof terapi (edit)
SARS-CoV-2 (edit) Human neutralizing antibodies elicited by SARS-CoV-2 infection (edit)
SARS-CoV-2 (edit) Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate (edit)
SARS-CoV-2 (edit) Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 (edit)
SARS-CoV-2 (edit) Potently neutralizing and protective human antibodies against SARS-CoV-2 (edit)
SARS-CoV-2 (edit) Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals (edit)
SARS-CoV-2 (edit) Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 (edit)
SARS-CoV-2 (edit) Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 (edit)

Ejemplos de código


curl -s | sed 's+<lang/>+es+' > antibodies.rq

curl -H "Accept: text/tab-separated-values" -G --data-urlencode query@antibodies.rq

Esta consulta SPARQL está disponible en CCZero.